HKPD vs HIMS vs TDOC vs OPRX

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 24.

6x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus HKPD's -77. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the lower-risk stock at 1.

66β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 44% more volatile than HKPD relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -101. 7% for Hong Kong Pharma Digital Technology Holdings Limited. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -7. 9% for Teladoc Health, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.

0x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 44. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HKPD: -77. 3%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HKPD (Industrials) and HIMS (Healthcare) and TDOC (Healthcare) and OPRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HKPD is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.